Dimensional Fund Advisors LP Has $13.49 Million Stock Holdings in OrthoPediatrics Corp. (NASDAQ:KIDS)

Dimensional Fund Advisors LP trimmed its stake in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 7.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 469,051 shares of the company's stock after selling 37,769 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.97% of OrthoPediatrics worth $13,490,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Wasatch Advisors LP raised its holdings in shares of OrthoPediatrics by 21.2% in the 1st quarter. Wasatch Advisors LP now owns 501,310 shares of the company's stock valued at $14,618,000 after purchasing an additional 87,657 shares during the period. Harbor Capital Advisors Inc. lifted its position in shares of OrthoPediatrics by 649.0% in the second quarter. Harbor Capital Advisors Inc. now owns 67,057 shares of the company's stock valued at $1,929,000 after buying an additional 58,104 shares during the last quarter. Kennedy Capital Management LLC bought a new position in shares of OrthoPediatrics during the 1st quarter worth approximately $2,894,000. Braidwell LP increased its holdings in shares of OrthoPediatrics by 4.7% during the 4th quarter. Braidwell LP now owns 1,107,770 shares of the company's stock worth $36,014,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of OrthoPediatrics during the 4th quarter worth approximately $10,214,000. Institutional investors and hedge funds own 69.05% of the company's stock.

Insider Activity

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 10,000 shares of the company's stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $29.30, for a total transaction of $293,000.00. Following the completion of the sale, the general counsel now directly owns 77,304 shares in the company, valued at $2,265,007.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 31.80% of the company's stock.

OrthoPediatrics Price Performance

OrthoPediatrics stock traded up $0.29 during mid-day trading on Friday, reaching $25.93. 94,882 shares of the company were exchanged, compared to its average volume of 169,091. The company has a fifty day simple moving average of $29.16 and a 200-day simple moving average of $30.21. The firm has a market cap of $617.89 million, a PE ratio of -27.01 and a beta of 1.17. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.90 and a quick ratio of 1.96. OrthoPediatrics Corp. has a 12 month low of $23.10 and a 12 month high of $36.23.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.08. OrthoPediatrics had a negative return on equity of 5.44% and a negative net margin of 14.35%. The business had revenue of $52.80 million during the quarter, compared to the consensus estimate of $52.40 million. As a group, equities research analysts expect that OrthoPediatrics Corp. will post -0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KIDS has been the subject of a number of research analyst reports. Truist Financial reaffirmed a "hold" rating and set a $34.00 price objective (up from $30.00) on shares of OrthoPediatrics in a research report on Friday, September 13th. JMP Securities reissued a "market outperform" rating and issued a $50.00 target price on shares of OrthoPediatrics in a research report on Friday, September 13th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price target on shares of OrthoPediatrics in a research report on Friday, September 13th.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.